ADVB Advanced Biomed: רווח למניה לשנה מתגלגלת

Advanced Biomed Inc (ADVB) is developing microfluidic systems for rapid blood cancer analysis, generating revenue from consumables. On GURU.Markets, this annual EPS TTM shift reflects a trend where the metric remains around 14.60. However, the pre-commercial development stage limits profit scaling. Investors should consider the risks of clinical failures and the company's dependence on external financing.

For Advanced Biomed Inc (ADVB), whose model depends on risky clinical trials, the 12-month YoY EPS growth rate reflects the company's ability to convert external capital into actual profit. This indicator compares net earnings per share over the last four quarters with the same period last year, allowing investors to promptly identify asset stagnation amid the high uncertainty of medical developments.